For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for DaVita Inc. (DVA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +23 (−100…+100 Quality+Value blend) · Quality 10 · Value 31 · Sentiment -57 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
DaVita Inc.
DVA NYSEDaVita Inc. is a healthcare services company specializing in kidney care, with a primary focus on providing dialysis treatments for patients with chronic kidney failure and end-stage renal disease. The company operates a large network of outpatient dialysis centers, where it delivers in-center hemodialysis and related care services to adult patients across the United States and internationally. DaVita Inc. also supports home-based dialysis modalities, offering peritoneal dialysis and home hemodialysis, along with clinical education and support programs to help patients manage treatment outside the clinic setting. In addition, the company operates clinical laboratories that perform routine and specialized tests for dialysis patients and provides management and administrative services to affiliated outpatient centers. Headquartered in Denver, Colorado, DaVita Inc. plays a significant role in the healthcare system by serving a critical, medically complex patient population and working alongside physicians, hospitals, and payers to coordinate kidney care and related services.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.84
Total Equity: $1.16B
Shares: 75,885,000
Total Debt: $0.00
Cash: $676.44M
EBITDA: $2.75B
Total Debt: $0.00
Cash: $676.44M
Revenue: $13.64B
Revenue: $13.64B
Revenue: $13.64B
Total Equity: $1.16B
Tax Rate: 21.8%
Equity: $1.16B
Total Debt: $0.00
Cash: $676.44M
Current Liabilities: $3.14B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $1.16B
Shares: 75,885,000
Shares: 75,885,000
CapEx: -$575.86M
Shares: 75,885,000
Stock Price: $180.06
Net Income: $746.80M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 10:51am (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $9.8B | $10.3B | $10.5B | $10.7B | $11.6B |
| Operating Income | $1.8B | $1.3B | $1.6B | $2.1B | $2.0B |
| Net Income | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| EBITDA | $2.5B | $2.1B | $2.3B | $2.8B | $2.8B |
| EPS | $9.30 | $6.03 | $7.62 | $11.02 | $10.06 |
| EPS (Diluted) | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 10:23am (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $461.9M | $244.1M | $380.1M | $794.9M | $676.4M |
| Total Current Assets | $3.2B | $3.2B | $3.1B | $3.7B | $4.1B |
| Total Assets | $17.1B | $16.9B | $16.9B | $17.3B | $17.5B |
| Current Liabilities | $2.4B | $2.6B | $2.6B | $3.0B | $3.1B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $14.8B | $14.7B | $14.2B | $15.2B | $16.3B |
| Total Equity | $2.4B | $2.2B | $2.7B | $2.1B | $1.2B |
| Retained Earnings | $354.3M | $174.5M | $598.3M | $1.5B | -$328.4M |
Cash Flow (Annual)
Last updated: Aug 15, 2026 10:51am (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.9B | $1.6B | $2.1B | $2.0B | $1.9B |
| Capital Expenditure | -$641.5M | -$603.4M | -$568.0M | -$555.4M | -$575.9M |
| Free Cash Flow | $1.3B | $961.1M | $1.5B | $1.5B | $1.3B |
| Acquisitions (net) | — | -$57.3M | -$26.4M | -$246.1M | -$117.5M |
| Net Debt Issued / (Repaid) | $1.6B | $2.4B | $2.5B | $6.6B | $5.6B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Stock Buybacks | -$1.5B | -$802.2M | -$272.2M | -$1.4B | -$1.3B |
| Net Change in Cash | $53.2M | -$216.0M | $125.6M | $415.2M | -$122.1M |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 10:51am (53d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -0.1% | +4.6% | +5.6% | +6.5% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -25.5% | +19.7% | +30.4% | -2.2% |
| Net Income Growth | -42.7% | +23.4% | +35.4% | -20.2% |
| EBITDA Growth | -16.4% | +13.5% | +20.0% | -2.0% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-17 16:23The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
DaVita's raw numbers tell a more ambiguous story than the synthesis "undervalued +98%" verdict implies. Revenue grew 6.4% in 2025 ($13.64B vs $12.82B), but net income *fell* 20% ($747M vs $936M), and the last four quarters show margin compression from 7.9% in Q4 2024 to 5.8% in Q1 2026 — with Q3 2025 bottoming at 4.4%. Operating margin at 14.98% is respectable but earnings CAGR of 3.9% and FCF CAGR of *negative 6.2%* undercut the "mature earner throwing off cash" framing. This is a business whose top line is growing modestly while unit economics deteriorate — the opposite of operating leverage. Free cash flow of $1.31B on an $11.56B market cap is a 11.3% FCF yield, which is genuinely cheap, but only if you believe the FCF stabilizes rather than continues its downtrend.
The valuation synthesis calling fair value $301-$357 is, frankly, absurd on its face and I dissent from it directly. An EV/EBITDA of 4.6x and P/E of 18.3x are not screaming-cheap for a business with 3.4% ROIC (yes, that's ROIC not ROE — the 64% ROE is a leverage artifact from the sliver of $1.16B equity supporting the balance sheet; debt is reported as zero which is clearly a data error given DaVita's well-known ~$9B debt load). A DCF spitting out $300+ almost certainly extrapolates recent FCF without penalizing the negative FCF trajectory or accounting for the actual capital structure. The thesis evaluation's score of +4 (essentially neutral) and the narrative layer's "fragile fallen-angel" read are far more honest — the market is discounting real risks (CMS reimbursement, wage inflation, GLP-1 impact on diabetic ESRD incidence), not being irrational.
The contrarian-to-the-contrarian case: what if the bulls are right that worst-case is priced in? DaVita and Fresenius run ~70% of US clinics, patient demand is inelastic, Berkshire owns ~45% of the float (a fact conspicuously absent from these outputs — that concentration structurally supports the price and explains buyback-driven EPS math). Q4 2025 net income of $234M annualizes to ~$940M, close to 2024's peak, suggesting the Q3 dip was transitory. At $180 with ~64M diluted shares, buybacks have shrunk the count meaningfully and any margin normalization back to 7% net levels would put earnings near $1B — a 12x multiple on that is $190-$200, not $300+. So the honest bull case is "10-20% upside plus buyback compounding," not "double."
The insider selling in June 2026 (~85K shares across multiple sellers within days) is a legitimate yellow flag the synthesis glossed over — insiders don't sell in size when they think the stock is worth $300. The stale/error-flagged debt figure of zero is disqualifying for any EV-based multiple without adjustment; real EV is closer to $20B, making EV/EBITDA closer to 7-8x, not 4.6x. That single correction cuts the "cheapness" argument in half. GLP-1s are a real 5-10 year TAM threat that no DCF built on 2% terminal growth captures. My verdict: the stock is modestly undervalued on a normalized-earnings basis but nowhere near the synthesis fair value; fair value is $200-$220, offering 15-25% upside plus a ~3% dividend equivalent via buybacks, which is a decent risk-adjusted return but not a table-pound. I partially agree with direction, strongly dissent on magnitude.
GPT Reading
DaVita looks cheaper than it feels, but not nearly as cheap as the model says. The business is clearly resilient on the top line: revenue has climbed from $11.6B in 2022 to $13.6B in 2025, and the last four reported quarters sum to roughly $13.8B with the March 2026 quarter up 6.2% year over year to $3.42B. That is a solid result for a mature dialysis operator. Cash generation is also real, with $1.89B of operating cash flow and $1.31B of free cash flow in 2025 against a $11.6B equity value, which is an eye-catching ~11% FCF yield. If I stopped there, the stock at $180 would look obviously mispriced. But the earnings line is weaker than the cash line: 2025 net income fell to $746.8M from $936.3M in 2024 despite 6.4% revenue growth, operating income slipped from $2.09B to $2.04B, and the most recent quarter’s net income of $197.5M was down 20% from $247M-ish a year ago on only modestly higher sales. This is not a business compounding profitability; it is a business working hard to hold it.
The quarterly pattern tells the story more clearly than the annual snapshot. Revenue has steadily risen from $3.19B in mid-2024 to $3.62B in 4Q25, then held at $3.42B in 1Q26, but net margin has compressed from a 6.6%-7.9% range in 2024 to 4.4%-6.5% through 2025 and 5.8% in the latest quarter. That matters because DaVita’s equity story only works if a slow-growth revenue base can throw off stable margins and heavy cash. Instead, every extra dollar of revenue appears less valuable than it was a year ago. The low EV/EBITDA of 4.6x and EV/revenue below 1x look optically cheap, but those multiples are exactly what I would expect for a regulated, labor-intensive service company with limited organic growth and real reimbursement risk. The market is not “missing” the business; it is discounting the fact that a 15.0% operating margin and 5.5% net margin may be closer to peak-ish normalized earnings power than to a new floor.
What also stands out is that some of the canonical metrics are flattering in ways that do not improve the investment case. A 64% ROE and 11.8x book value are mostly artifacts of a very small $1.16B equity base, not proof of exceptional economics. At the same time, the reported ROIC of 3.3% is the more telling figure: this is not a high-return compounder, it is a decent cash harvester. That distinction is why I reject the near-$300 to $350 fair value output. A company growing revenue 6%, earnings under 4% over several years, and free cash flow actually shrinking at a 6.2% CAGR should not be awarded a valuation that implies the market is irrationally pessimistic. At $180, investors are paying about 18x trailing earnings for a mature operator whose earnings have become more volatile and whose latest quarter showed profit contraction. That is not expensive enough to short aggressively, but it is also not the screaming value the synthesis claims.
The best counterargument is straightforward and serious: free cash flow is what matters here, and on that measure DaVita looks undeniably attractive. $1.31B of FCF on an enterprise value implied by 4.6x EBITDA can support substantial buybacks, debt service if needed, and equity compounding even in a no-growth world. Revenue has been consistent, the business is essential, and the gap between operating cash flow of $1.89B and net income of $746.8M suggests earnings may understate economic value because of non-cash charges. If labor inflation has largely rolled through and reimbursement pressure merely stabilizes rather than worsens, then even flat margins could make today’s valuation too low. I take that seriously; it is the main reason I am not bearish. But I weigh it differently because the recent earnings trajectory is not noise: 2025 operating income declined despite higher revenue, and 1Q26 profit was down sharply year over year. In a business this mature, “stable enough” is not enough to justify a big rerating unless margin stability is visible in the reported numbers, not just inferred from cash flow.
What would change my mind is simple. If the next two quarters show revenue still in the $3.4B-$3.5B range but net income recovering back above $220M per quarter with net margins consistently above 6.5%, I would move bullish because that would suggest 2025 was a temporary dip rather than a structural squeeze. Likewise, if annual free cash flow can stay at or above $1.3B without further deterioration in operating income, then the cash-yield argument wins. On the other hand, if revenue keeps growing mid-single digits while quarterly net margins stay stuck around 5% or fall below that, the stock should trade closer to 14x-15x earnings, which points more toward $145-$160 than $180.
Grok Reading
The numbers describe a mature cash compounder that is growing the top line but losing ground on the bottom line. Revenue climbed from $11.62B in 2021 to $13.64B in 2025—a clean ~6% CAGR—and the last four reported quarters sit in a tight $3.22–3.62B band, with Q1 2026 still printing $3.42B. That is not a demand story in freefall. What is fraying is conversion: net income fell from $936M in 2024 to $747M in 2025 (−20% YoY), net margin compressed from the mid-7% zone into the mid-5s, and FCF CAGR is already negative at −6.2% even though absolute FCF remains a sturdy $1.31B against only $576M of capex. Operating cash flow of $1.89B still dwarfs the equity base of $1.16B, which is why ROE prints an optically absurd 64% and why the stock can look cheap on cash metrics while looking expensive on book. At $180 and an $11.56B market cap the shares trade at 18.3× earnings, ~1.0× sales, and 4.6× EV/EBITDA—multiples that price in permanent margin damage rather than a cyclical labor/reimbursement squeeze. The business is a scale dialysis franchise with captive, non-discretionary volume; the market is not arguing about that. It is arguing that Medicare is a structural short and that every dollar of wage inflation or rate cut falls straight through a thin net margin.
I do not buy the model composite fair value near $302–$357. That implies nearly a double from here on a franchise whose earnings just shrank 20%, whose FCF is contracting on a multi-year basis, and whose insider tape is a wall of sales (roughly 85k shares disposed in mid-June 2026 alone, against trivial award grants). A reverse-DCF that has to assume sustained FCF decline to justify $180 is too punitive given $1.3B of current free cash and a duopoly volume base, but leaping to a 98% upside target ignores that operating income already rolled over ($2.09B → $2.04B) and that net margin has not reclaimed 2024 levels. Fair value closer to the mid-$220s—call it low-teens FCF yield compression plus modest multiple expansion if margins stabilize—is the more honest anchor. That still leaves the stock undervalued, just not dramatically so. The PB of 11.8 and the zeroed debt/equity field are data artifacts of a hollowed-out equity account after years of buybacks and leverage; they should not be used as primary valuation inputs. EV/EBITDA at 4.6× and FCF yield near 11% are the real signals, and they say the market has over-penalized a still-generating cash machine.
The strongest opposing case is straightforward and material. Earnings power has already proven fragile: 2025 NI of $747M is closer to the weak 2022–23 trough than to the 2021 or 2024 peaks, and quarterly margins have swung from 7.9% down to 4.4% within five quarters. FCF declining at a mid-single-digit CAGR while revenue grows is the textbook definition of a business absorbing permanent cost or rate pressure. GLP-1 therapies that slow diabetic nephropathy are a multi-year TAM risk the models underweight; Medicare rate settlements can erase a year of margin progress in a single CMS update; and the narrative layer correctly flags that this is a fallen-angel story with fragile durability—any missed guide or labor spike confirms the bear and the discount widens, not tightens. Insider selling is not noise. A smart opponent would say $180 is fair for a 3–4% earnings grower with regulatory overhang and a shrinking long-term patient pool, and that 4.6× EV/EBITDA is a value trap multiple, not a bargain. I weigh that case seriously but still come out the other side because absolute FCF of $1.3B on an $11.6B equity value, steady 6%+ revenue, and a non-discretionary clinical franchise are hard to reconcile with permanent impairment pricing unless margins collapse another 200 bp from here—which the recent quarterly run-rate ($150–234M NI per quarter) does not yet show.
What flips the verdict: four consecutive quarters of net margin back above 6.5% with FCF holding above $1.4B annualized would force a re-rating toward $240+ and make me more aggressive; a CMS dialysis rate cut, another 15%+ NI decline in 2026, or clear volume attrition tied to GLP-1 penetration would push me to fairly valued or worse at this price.
Qwen Reading local experiment · off-panel
The number that should be doing the heavy lifting in this read is the free cash flow yield: $1.31 billion of FCF against an $11.56 billion market cap is an 11.3% yield, and that is not a number you see in a duopoly with 250,000+ captive patients and 5–6% revenue growth. Revenue has compounded at roughly 6% every single year from 2021's $11.62 billion to 2025's $13.64 billion, and Q1 2026's $3.42 billion (up 6.2% year-over-year from $3.22 billion) confirms the trend is intact. Operating cash flow of $1.89 billion against capex of $576 million is a clean, capital-light-ish conversion for a clinic operator, and the 15% operating margin in 2025, while down from 2024's 16.3%, is still well above the 11.5% trough of 2022. The market is paying 4.6x EV/EBITDA and 1.0x sales for a business with zero revenue elasticity and a structural duopoly. That is cheap. The valuation synthesis engine's $302–$357 fair-value range is, frankly, absurd — it implies a 20x+ FCF multiple on a company whose FCF CAGR is *negative* at -6.2%, and I would not underwrite that. But the engine's directional call that the stock is below intrinsic value is correct; I just think the anchor is $200–$220, not $350.
The data that genuinely worries me is the earnings trajectory, and I want to be precise about it. Net income went from $978.5 million in 2021 to $560.4 million in 2022, recovered to $691.5 million in 2023, spiked to $936.3 million in 2024, and then *fell* to $746.8 million in 2025 — a 20% decline. The quarterly pattern in 2025 is ugly: Q3 was a $150.3 million quarter (4.4% margin), the worst in the eight-quarter window. The encouraging counterpoint is Q1 2026 at $197.5 million, up 21% from Q1 2025's $162.9 million, which suggests the 2025 dip was a labor-cost or one-time item rather than a structural break. But I am not going to pretend the 2024→2025 earnings decline is noise. The FCF CAGR of -6.2% over the trailing period is the single most important number in this briefing, and it tells me the market's skepticism about margin sustainability is not pure sentiment. The "fallen angel" narrative the engine identified is partially right: this stock de-rated 27% from its 52-week high because the earnings inflection was real, not imagined.
The strongest case against my read is straightforward and I will not wave it away. A smart opponent points to the -6.2% FCF CAGR and says: "You are buying a peak-yield value trap." They point to the 2025 net income decline and say the 2024 print of $936 million was the cyclical top, not the floor. They cite the insider selling — roughly 85,000 shares liquidated in mid-June 2026, about $15 million at current prices — as insiders knowing something about the labor-cost trajectory that the 10-K doesn't yet reflect. They note the ROIC of 332% and ROE of 64.5% are capital-structure artifacts (total equity is only $1.16 billion, debt data is missing from the filing) and that the true return on invested capital, once you reconstruct the balance sheet, is closer to 25–30%, which is good but not extraordinary for a duopoly. And they raise the GLP-1 / home-dialysis TAM question: even if GLP-1s don't reverse ESRD, the slow migration of stable patients to home peritoneal or home hemodialysis erodes the per-patient revenue that underpins the 15% operating margin. I weigh these concerns seriously, but I disagree with the conclusion that they justify a sub-$150 price. The duopoly structure means even a 10% patient-mix shift toward home dialysis is absorbed by the other player, not by a new entrant. And the insider sales, while directionally negative, are small relative to the float and consistent with routine portfolio diversification at a company this size.
What would change my mind in either direction. On the bear side: if Q2 2026 (reporting around late July) shows net income below $150 million again — i.e., the Q1 2026 recovery was a one-quarter blip and the 2025 margin compression is the new steady state — I would downgrade to fairly valued or overvalued, because the 11.3% FCF yield would be a peak, not a floor, and the -6.2% FCF CAGR would be confirmed as a trend. A CMS reimbursement cut of even 2–3% in the 2027 rate cycle would be the other trigger; at 15% operating margins, a 3% revenue hit is roughly a 20% operating-income hit, and the stock would have no cushion. On the bull side: if Q2 2026 shows operating margin back above 16% and management guides to FCF growth of 5%+ for 2026, the FCF CAGR inflects positive, and the stock re-rates toward $210–$220 on a 12–13x FCF multiple, which I would consider the fair-value ceiling for this business. A concrete home-dialysis penetration data point showing the shift is below 5% of total patient volume would also kill the TAM-erosion bear case and support a re-rating.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
DaVita is a mature, highly cash-generative operator: revenue grew from 11.62B in 2021 to 13.64B in 2025, operating margin oscillates in a healthy 11.5-16.3% band, and FCF has been 0.96-1.49B every year. OCF/NI of 2.49x and accruals at -6.5% of assets indicate reported earnings are backed by real cash, not aggressive accounting. The capital allocation story is dominated by buybacks: diluted share count fell from 109.9M to 75.9M (about -8.9% CAGR), and buyback dollars are roughly 960% of SBC, so per-share economics are concentrating meaningfully. The concern is the balance sheet. With only 700M cash against an 11.6B market cap and Altman Z at 1.63 (distress zone), the buyback engine is being funded by leverage, not surplus cash. This is a deliberate levered-equity-shrink model rather than a fortress. Net income was choppy (560M in 2022, 936M in 2024, back down to 747M in 2025), suggesting the underlying dialysis business has more earnings variability than the top line implies. Insider behavior tilts negative: 9 sales for 35M and zero open-market buys in the last 12 months, including multiple large disposals by Rodriguez and Hearty. Not catastrophic for a mature comp plan, but no one is stepping up to buy.
Verify before trusting this (6)
- Total debt, maturity ladder, and covenants - the buyback appears debt-funded
- Medicare/commercial payer mix and any pending CMS rate actions
- Customer/geographic concentration and clinic-level unit economics from the 10-K
- Whether the 2025 net income dip vs 2024 reflects labor, rate, or one-time items
- 10b5-1 status of the Rodriguez and Hearty sales and their remaining ownership levels
- IKC / integrated kidney care segment economics and losses
The e2e composite fair value of $301.83 and signal-adjusted $356.67 imply ~70-98% upside, but I discount the DCF ($336.61) as too generous for a business facing CMS reimbursement pressure, labor inflation, and a genuine home-dialysis disruption tail. The EPV floor of $232.26 is the more defensible anchor - it captures the durable cash generation (1.3B FCF) without heroic growth assumptions. Against the $180.06 price, that EPV implies roughly 29% upside, which is a real margin of safety but not a fat-pitch dislocation. Quality is Solid but the Altman Z of 1.63 and thin cash cushion argue for hair-cutting deserved value, not extending it. The buyback (share count down 31% in four years) mechanically compounds per-share value at these prices, which is the strongest cheap signal - management is voting with the balance sheet. Priced-in expectations look modest: flat-to-declining volumes, margin compression, and continued deleveraging. That is a low bar the business should clear. Not a screaming bargain, but a defensible discount to a deserved value in the $230-260 range.
Verify before trusting this (5)
- CMS bundled payment updates and any 2025 rate guidance
- Home dialysis adoption trajectory in earnings commentary
- FCF conversion and buyback pace vs debt paydown priorities
- Insider selling pattern - is it programmatic or opportunistic
- Labor cost trend in operating expense detail
The macro tape is mildly risk-on with VIX at 14.3 and the S&P near highs, but that's exactly the regime that leaves a low-beta (0.87), defensive-but-broken healthcare name like DVA behind. Money is chasing AI and mega-cap growth (see Berkshire piling into Alphabet); a low-multiple dialysis operator with a fragile story gets no bid from this tape. The narrative is the dominant force here: fallen-angel archetype, moderate intensity, fragile durability, low cult - meaning few holders will defend it on weakness, and the marginal buyer needs to be convinced, not excited.
Verify before trusting this (4)
- Whether sell-side revises down after the negative Q2 reaction (target cuts would confirm headwind)
- Any CMS or reimbursement headline in coming weeks
- Signs of home-dialysis adoption acceleration from peers
- Berkshire 13F treatment of the DVA stake under Abel
The world is doing two contradictory things to DaVita. Near-term it is friendly: chronic-disease prevalence keeps the ESRD pool full, the bundle indexes upward, and a duopoly structure with inelastic demand is one of the few places in healthcare where volume risk is near-zero. Structurally it is unfriendly: the same pharmacological wave (GLP-1s, SGLT2 inhibitors) that is making diabetes management better is designed to keep patients out of dialysis chairs, and payor and policy pressure runs one direction — down on rates. Capital is flowing to acute and payor-adjacent healthcare assets growing double digits, not to a rate-taking clinic network. So the honest read is a slow, defensible annuity with a governor on it: revenue grows because price grows, earnings per share grow because the share count shrinks, and the terminal growth rate is the real debate. That is a materially better business than a -10% price-implied trajectory describes, and materially worse than the category it is filed under.
Prediction unavailable. valuation-synthesis has no result for DVA — the prediction needs its fair-value anchors.